Abstract: Objective　To evaluate the efficacy and safety of crisaborole ointment in the treatment of children with mild to moderate atopic dermatitis（AD）. Methods　A total of 137 children with mild to moderate AD who were admitted to the Department of Dermatology of Tianjin Children’s Hospital from January 2020 to March 2021 were recruited，and they were divided into the experimental group（n=65） and the control group（n=72）. The experimental group was treated with crisaborole ointment，while the control group was treated with hydrocortisone butyrate cream. After 2 weeks of treatment，the success rate of treatment，the time required to achieve successful treatment，the differences in scores of SCORAD before and after treatment，and the incidence of adverse reactions were compared between the two groups. Results　After 2 weeks of treatment，the success rate of the experimental group（73.8%，48/65） was higher than that of the control group（55.6%，40/72），and the difference was statistically significant（P<0.05）. The time to achieve successful treatment of the experimental group was less than that of the control group，and the difference was statistically significant（P<0.05）. SCORAD score of the experimental group（4.8±3.4） was lower than that of the control group（7.5±2.9） after treatment, and the difference was statistically significant（P<0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion　The treatment for children with mild to moderate AD with crisaborole ointment has a great clinical effect and is worthy of clinical promotion.

Key words: atopic dermatitis, child, crisaborole, treatment, SCORAD scores

摘要： 目的　观察评估克立硼罗软膏在治疗儿童轻中度特应性皮炎（atopic dermatitis，AD）中的疗效及安全性。方法　选取2020年1月至2021年3月天津市儿童医院皮肤科接受治疗的137例轻中度AD患儿为研究对象，分为观察组65例和对照组72例。观察组采用克立硼罗软膏治疗，对照组采用丁酸氢化考的松乳膏治疗，比较两组治疗2 周后治疗成功率、达到治疗成功所需时间、治疗前后SCORAD评分差异及药物不良反应发生率等指标。结果　观察组治疗2周后治疗成功率（73.8%，48/65）高于对照组（55.6%，40/72），差异有统计学意义（P <0.05）；观察组达到治疗成功所需时间少于对照组，差异有统计学意义（P <0.05）；治疗后观察组SCORAD评分（4.8±3.4）低于对照组（7.5±2.9），差异有统计学意义（P <0.05）；两组药物不良反应发生率比较差异无统计学意义（P >0.05）。结论　轻中度AD患儿给予克立硼罗软膏疗效较好，值得临床推广应用。

关键词: 特应性皮炎, 儿童, 克立硼罗, 治疗, SCORAD评分